BMS-986406 + Combination Therapies for Cancer

Recruiting in Palo Alto (17 mi)

+51 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Bristol-Myers Squibb

No Placebo Group

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

This trial is testing a new drug called BMS-986406 alone, with an immune-boosting drug called nivolumab, or with both nivolumab and strong chemotherapy. It targets patients with advanced cancer. The goal is to see if these treatments are safe and can help stop cancer growth by boosting the immune system and killing cancer cells. Nivolumab has been used in various cancer treatments and has shown efficacy in improving survival rates, especially when combined with other therapies.

Research Team

Bristol-Myers Squibb

Principal Investigator

Bristol-Myers Squibb

Eligibility Criteria

This trial is for adults with certain advanced cancers, including lung, kidney, pancreatic, and others. Participants must have a confirmed diagnosis with measurable disease and be in good physical condition. They can't join if they have untreated brain metastases, prior organ transplants or serious medical issues that aren't under control.

Inclusion Criteria

I have Stage IV A/B non-small cell lung cancer or recurrent disease and haven't had systemic therapy for it.

My cancer is advanced and cannot be removed by surgery, but it hasn't spread to my brain.

My cancer can be measured using specific medical guidelines.

Exclusion Criteria

Other protocol-defined inclusion/exclusion criteria apply

I have received an organ or tissue transplant from another person.

I have brain metastases that have not been treated.

Treatment Details

Interventions

• BMS-986406 (Monoclonal Antibodies)
• Nivolumab (Monoclonal Antibodies)

Trial Overview The study tests BMS-986406 alone or combined with Nivolumab and/or platinum-doublet chemotherapy (PDCT) to see how safe it is and how well people tolerate it. It's aimed at those with advanced tumors to find better treatment options.

Participant Groups

Group I: Part 2: BMS-986406 + Nivolumab (Expansion Cohorts) Experimental Treatment 2 Interventions

Group II: Part 1D: BMS-986406 + Nivolumab + Carboplatin with Pemetrexed or Paclitaxel Experimental Treatment 5 Interventions

Group III: Part 1C: BMS-986406 + Nivolumab (Indication-Specific Dose Expansion) Experimental Treatment 2 Interventions

Group IV: Part 1B: BMS-986406 + Nivolumab (Combination Dose Escalation) Experimental Treatment 2 Interventions

Group V: Part 1A: BMS-986406 (Monotherapy Dose Escalation) Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

Bristol-Myers Squibb

Lead Sponsor

Trials

2,731

Recruited

4,127,000+

Headquarters

New York City, USA

Known For

Oncology & Cardiovascular

Top Products

Eliquis, Opdivo, Revlimid, Orencia

Christopher Boerner

Bristol-Myers Squibb

Chief Executive Officer since 2023

PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis

Deepak L. Bhatt

Bristol-Myers Squibb

Chief Medical Officer since 2024

MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania